Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics

@article{Obach2010MetabolismOR,
  title={Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics},
  author={R. Obach and Tim F. Ryder},
  journal={Drug Metabolism and Disposition},
  year={2010},
  volume={38},
  pages={1381 - 1391}
}
Ramelteon is a melatonin receptor agonist used as a treatment for insomnia. It is subject to a remarkably large drug-drug interaction (DDI) caused by fluvoxamine coadministration, resulting in a more than 100-fold increase in exposure. The objective of this study was to determine whether the DDI could be estimated using in vitro metabolism data. Ramelteon was shown to undergo hydroxylation in human liver microsomes to eight metabolites via six pathways. The main routes of metabolism included… Expand
Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2‐ and CYP3A4‐selective Inhibitors
TLDR
The findings suggest that the intrinsic activities of CYPs 1A2 and 3A4 are unrelated to the response to CYP‐selective inhibitors and that assessment of the activities in vivo may not assist the prediction of drug–drug interactions. Expand
Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice
TLDR
An enzyme kinetic-based model is developed to enable more accurate prediction of the fate of new chemicals in humans and which can be validated in vivo using mice humanized for cytochrome P450–mediated metabolism. Expand
Effects of selective serotonin reuptake inhibitors on the pharmacokinetics of proton pump inhibitors
By now, the differential effects of several selective serotonin reuptake inhibitors (SSRIs) on the cytochrome P450 (CYP) enzymes are well defined and that the drug-drug interactions (DDIs) are aExpand
Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
TLDR
An up-to-date summary on the expression, regulation, function, and drug–drug interactions of CYP1A enzymes in humans is provided. Expand
Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
  • K. Iga
  • Chemistry, Medicine
  • Journal of pharmaceutical sciences
  • 2015
TLDR
Despite large differences in AUCRs, CYP1A2 or CYP2C19 substrate-victimized DDIs resulted in equivalent inhibition constants and net enzymatic inhibitory activities calculated by eliminating hepatic availability increases for victims, suggesting the usefulness of a tube-based static method for DDI prediction. Expand
Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability
TLDR
A facile two-step method of inserting fluorine into metabolically labile sites of drug molecules is described that utilizes less than 1 mg of starting material and quantitative NMR spectroscopy to ascertain the structures and concentrations of products. Expand
Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers
TLDR
In insights into the interaction profiles of drugs poorly studied so far are provided and can help to identify and manage significant interactions in clinical practice. Expand
Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products
TLDR
Clinical studies are needed in order to determine the effects of other drugs on pharmacokinetics and pharmacodynamics of marijuana and cannabis products, with a significant increase in the USA due to the increasing number of states that allow medical and recreational use. Expand
The natural anthraquinones from Rheum palmatum induced the metabolic disorder of melatonin by inhibiting human CYP and SULT enzymes.
TLDR
It is elucidated that herbs or foods containing abundant anthraquinones such as R. palmatum will cause a metabolic disorder of Mel, and should be avoided to combined application with Mel in clinic. Expand
Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: Solving substrate interactions of CYP1A2 with non-PAH substrates on the template system.
TLDR
Present CYP1A2 Template system offers a unified evaluation of human CYP2A2 ligands, which aids for toxicological assessments as well as drug metabolism studies, irrespective of their shapes and flexibilities. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 27 REFERENCES
Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes
TLDR
There is a significant difference in the fluvoxamine‐mediated percentage increase in the AUC0‐∞ of lansoprazole between CYP2C19 genotypes and the present study indicates that there are significant drug interactions between lansOPrazole and fluVoxamine in EMs. Expand
Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.
TLDR
TCAs appear to have minimal potential for MBI of human liver microsomal CYP enzymes involved in drug metabolism, and HLM and recombinant CYP are not equivalent enzyme sources for evaluating the TDI associated with some drugs. Expand
Effect of fluconazole on theophylline disposition in humans
TLDR
The results indicate that fluconazole is a minor inhibitor of theophylline disposition compared with enoxacin, and they suggest that the inhibitory action of fluconAZole is selective for certain cytochrome P-450 isozymes, but not for the cyto chrome P-4501A involved in theophyLLine metabolism. Expand
Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.
TLDR
Assessment of theophylline metabolism indeed serves as a biomarker for CYP1A2, and in four subjects a marked induction was seen for all pharmacokinetic parameters, suggesting that the susceptibility to induction is more pronounced in some subjects. Expand
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine
TLDR
The objective of this study was to evaluate the effect of liver cirrhosis on the inhibition by fluvoxamine of the metabolic disposition of theophylline, a CYP1A2 substrate with a low‐extraction ratio, to assess whether decreased sensitivity to CYP2A2 inhibition in liver disease is a general characteristic of CYP 1A2 substrates, regardless of their pharmacokinetic properties. Expand
Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination
TLDR
The data suggest that the hepatic accumulation of these inhibitors results from intracellular binding rather than the involvement of uptake transporters and indicate that microsomes and hepatocytes appear to be equivalent for determining the inhibitory potency of the six inhibitors investigated in the present study. Expand
The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone
TLDR
Fluvoxamine moderately increased plasma buspirone concentrations and decreased the production of the active 1-PP metabolite of buspir one, and this pharmacokinetic interaction was not associated with impairment of psychomotor performance and it is probably of limited clinical significance. Expand
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
TLDR
Findings support the conclusion that P450 in vitro inhibition data are valuable in designing clinical DDI study strategies and can be used to predict the magnitudes of DDI. Expand
Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
TLDR
It is suggested that the liver plays a much greater role in first-pass metabolism of indinavir than the intestine in both species, suggesting the involvement of CYP3A isoforms in both organs. Expand
APPLICATION OF THEOPHYLLINE METABOLITE ASSAYS TO THE EXPLORATION OF LIVER MICROSOME OXIDATIVE FUNCTION IN MAN
TLDR
The effects on theophylline oxidative metabolism of 3 inhibitors of liver microsome activity — cimetidine, troleandomycin and ketoconazole — were investigated in 6 healthy volunteers and measurement of theophyLLine metabolite formation clearances might be a useful test to explore liver micro some oxidative function. Expand
...
1
2
3
...